Category: Latest News
-

Creative Medical Receives U.S. Patent Allowance for Exosome-Based Type 1 Diabetes Immunotherapy
The new patent allowance expands intellectual property protection around Creative Medical’s diabetes pipeline while supporting its strategy across cell-based and cell-free immunotherapy platforms. Key Investor Takeaways Why CELZ Stock Is in Focus Creative Medical Technology Holdings (NASDAQ:CELZ) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application…
-

SoundHound AI Reports Record Q2 Revenue and Raises Full-Year Outlook on Enterprise AI Demand
Record quarterly revenue, accelerating enterprise adoption of its OASYS platform and stronger commercial execution prompted SoundHound AI to increase its 2026 revenue guidance. Key Investor Takeaways Why SOUN Stock Is in Focus SoundHound AI (NASDAQ:SOUN) reported record second-quarter revenue of $61.9 million, representing 45% year-over-year growth and marking the company’s highest quarterly revenue to date.…
-

Premier Graphene Announces Defense Manufacturing Joint Venture with Nova Graphene
The agreement expands Premier Graphene’s presence in advanced materials by targeting graphene-enabled ballistic protection systems and supporting its long-term vertical integration strategy. Key Investor Takeaways Why BIEI Stock Is in Focus Premier Graphene (USOTC:BIEI) announced that its affiliate, HGI Industrial Technologies, has entered into a strategic joint venture with Canada’s Nova Graphene to develop, manufacture…
-

American Fusion Expands Texatron Patent Portfolio with Six New U.S. Patent Applications
The company increased its U.S. patent portfolio to 82 applications while advancing regulatory, engineering and testing milestones for its Texatron Fusion Engine platform. Key Investor Takeaways Why (USOTC:AMFN) Stock Is in Focus American Fusion (USOTC:AMFN) announced the filing of six new U.S. patent applications related to its proprietary Texatron Fusion Engine platform, bringing its total…
-

VoIP-Pal Granted Leave to Amend Sherman Act Complaint in Antitrust Case Against Major U.S. Carriers
The court’s decision allows VoIP-Pal to refine its federal antitrust claims while narrowing the litigation to focus on alleged violations of the Sherman Act. Key Investor Takeaways Why (USOTC:VPLM) Stock Is in Focus VoIP-Pal.com (USOTC:VPLM) announced that the U.S. District Court for the District of Columbia has granted the company permission to file an amended…
-

Onfolio Holdings Announces 1-for-50 Reverse Stock Split to Regain Nasdaq Compliance
The reverse stock split is designed to restore compliance with Nasdaq’s minimum bid price requirement while reducing the company’s outstanding share count to approximately 850,000 shares. Key Investor Takeaways Why (NASDAQ:ONFO) Stock Is in Focus Onfolio Holdings (NASDAQ:ONFO) announced it will complete a 1-for-50 reverse stock split as part of its effort to regain compliance…
-

Commerce Reports Second-Quarter Profit as GMV Growth and AI Commerce Investments Support Outlook
The company delivered a second consecutive quarter of GAAP profitability while continuing to invest in AI-driven commerce capabilities and maintaining its full-year financial outlook. Key Investor Takeaways Why CMRC Stock Is in Focus Commerce (NASDAQ:CMRC) reported second-quarter revenue of $84.5 million, broadly unchanged from a year earlier, while Gross Merchandise Volume (GMV) increased 14% to…
-

Insmed Raises BRINSUPRI Revenue Guidance After Strong Q2 Growth and Expands Peak Sales Outlook
Strong commercial momentum for BRINSUPRI and continued growth from ARIKAYCE prompted Insmed to raise its 2026 outlook and increase peak revenue expectations for its lead programmes. Key Investor Takeaways Why INSM Stock Is in Focus Insmed (NASDAQ:INSM) reported total second-quarter 2026 revenue of $425.5 million, driven by continued commercial strength from BRINSUPRI, which generated $309.2…
-

Iovance Biotherapeutics Reports Record Q2 Revenue and Reviews 2026 Outlook on Strong Amtagvi Demand
Record quarterly revenue, improving margins and continued commercial momentum are prompting Iovance to reassess its full-year guidance while advancing multiple late-stage clinical programmes. Key Investor Takeaways Why (NASDAQ:IOVA) Stock Is in Focus Iovance Biotherapeutics (NASDAQ:IOVA) delivered record second-quarter revenue of approximately $99.3 million, a 66% increase from the prior-year quarter and a 39% improvement over…
-

Roche Expands Cyclospora Testing Portfolio to Support U.S. Public Health Response
The healthcare company has introduced two new research-use PCR tests as demand for cyclospora detection grows during an ongoing U.S. outbreak. Key Investor Takeaways Why RHHBY Stock Is in Focus Roche (USOTC:RHHBY) announced the launch of two new real-time PCR assays designed to detect Cyclospora cayetanensis, the parasite responsible for cyclosporiasis, as laboratories seek additional…